Jeffrey Mahoney, MD
Clinical Cardiac Electrophysiology · Omaha, NENPI 1245291236
Payments from drug & device makers
Across 548 payments — averaging $217.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$67K
- E.r. Squibb & Sons, L.L.C.$29K
- Abbott$16K
- Medtronic$3K
- Atricure, Inc.$1K
- Novartis$801
- plus $3K from 28 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$500
What the payments were for
- Consulting fees$5000%
- Speaking & faculty fees$90,37577%
- Travel & lodging$5,3675%
- Food & beverage$21,52518%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 69 | $67,179 |
| E.r. Squibb & Sons, L.L.C. | 38 | $28,614 |
| Abbott | 218 | $16,223 |
| Medtronic | 26 | $2,573 |
| Atricure, Inc. | 8 | $1,101 |
| Novartis | 55 | $801 |
| Amgen | 35 | $486 |
| AstraZeneca | 7 | $435 |
| Sanofi-aventis U.S. LLC | 18 | $270 |
| Boston Scientific | 7 | $255 |
| Boehringer Ingelheim | 17 | $254 |
| Impulse Dynamics (USA) Inc. | 4 | $154 |
| Biosense Webster, Inc. | 1 | $126 |
| ZOLL Respicardia, Inc. | 1 | $123 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $74 |
| Actelion Pharmaceuticals US, Inc. | 4 | $67 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $65 |
| Stryker | 3 | $59 |
| Cardiva Medical, Inc. | 2 | $59 |
| Amarin Pharma, Inc. | 3 | $52 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Regeneron Healthcare Solutions, Inc. | 3 | $48 |
| Johnson & Johnson | 3 | $41 |
| Itamar Medical Inc | 1 | $35 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| Bridgebio Pharma, Inc. | 1 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $29 |
| Abiomed | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Zimmer Biomet | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$94,606
- AVEIR$2,048
- Quadra Assura CRT Defibrillator$1,814
- Confirm Rx$961
- Quadra Allure MP RF CRT Pacemkr$765
- Fortify Assura, Ellipse ICD$622
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$612
- QUADRA ALLURE MP$511
- QUADRA ASSURA$447
- FARXIGA$375
- Allure Quadra RF CRT Pacemaker$365
- Micra$354
- SYNERGY ABLATION SYSTEM$338
- Accent Pacemaker$309
- Assurity Pacemaker$185
- ATRICLIP LAA EXCLUSION SYSTEM$184
- ENSITE PRECISION$175
- Ensite Cardiac Mapping System$155
- AURORA EV-ICD MRI SURESCAN$148
- LINQ II$145
How this compares
$119,367 in reported general payments places this provider in the 65th percentile of 21 clinical cardiac electrophysiology providers in Nebraska.
See all clinical cardiac electrophysiology providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 920 | $878,823 |
| XareltoRivaroxaban | 159 | $157,077 |
| MultaqDronedarone Hcl | 59 | $89,448 |
| Flecainide Acetate | 678 | $32,565 |
| EntrestoSacubitril/Valsartan | 18 | $13,001 |
| Dofetilide | 78 | $12,782 |
| Amiodarone Hcl | 689 | $10,999 |
| Metoprolol Succinate | 488 | $5,344 |
| SotalolSotalol Hcl | 364 | $5,141 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 142 | $3,995 |
| Propafenone Hcl | 32 | $1,958 |
| Mexiletine Hcl | 14 | $1,292 |
| Diltiazem 24hr ErDiltiazem Hcl | 21 | $961 |
| Metoprolol Tartrate | 179 | $602 |
| Carvedilol | 94 | $553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $67,179 | $878,823920 claims |
| Johnson & JohnsonXarelto | $41 | $157,077159 claims |
| Sanofi-aventis U.S. LLCMultaq | $270 | $89,44859 claims |
| NovartisEntresto | $801 | $13,00118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 21 clinical cardiac electrophysiology providers in Nebraska.
Other clinical cardiac electrophysiology in Omaha
- Jason PayneOmaha$221K
- Shane TsaiOmaha$220K
- Hussam AbuissaOmaha$191K
- Matthew LatachaOmaha$151K
- David SternsOmaha$50K
- Matthew SorensenOmaha$30K
- John SchleiferOmaha$28K
- Matthew KapalisOmaha$24K
- Christopher EricksonOmaha$18K
- Daniel VariOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.